Kyntra Bio, Inc. reported a net loss of $3.2 million for the six months ended June 30, 2026, a significant improvement compared to a loss of $30.4 million during the same period in 2025. The company’s revenue for the first half of 2026 totaled $2.3 million, down 45% from $4.1 million in the prior year, primarily due to a decrease in drug product revenue. The company recorded a negative drug product revenue of $1.6 million for the second quarter of 2026, compared to $1.2 million in the same quarter of 2025. This decline was attributed to adjustments in variable consideration related to shipments under the Astellas Japan Agreement.
Operating costs and expenses increased to $33.7 million for the first half of 2026, up from $31.1 million in the previous year. The rise was driven by higher legal expenses related to indemnification costs associated with a former officer, as well as increased clinical trial expenses for the ongoing Phase 2 trials of FG-3246, a potential treatment for metastatic castration-resistant prostate cancer. The company also reported a gain of $30.9 million from the deconsolidation of its European subsidiary, FibroGen Europe, which filed for bankruptcy in April 2026.
Kyntra Bio has made strategic moves to enhance its operational focus, including a rebranding from FibroGen, Inc. to Kyntra Bio, Inc. in January 2026, and the initiation of a Phase 2 monotherapy dose optimization study for FG-3246. The company is also preparing for a Phase 3 trial for roxadustat, targeting anemia in lower-risk myelodysplastic syndromes, with plans to initiate the trial in the fourth quarter of 2026. The FDA granted Orphan Drug Designation for roxadustat in December 2025, which could provide regulatory and economic benefits.
As of June 30, 2026, Kyntra Bio reported total assets of $101.1 million, a decrease from $119.6 million at the end of 2025. The company’s cash and cash equivalents increased to $50.6 million, up from $47.9 million at the end of the previous year. The company’s liabilities totaled $109.2 million, with a significant portion related to a liability for the sale of future revenues. Kyntra Bio anticipates needing additional funding to support its ongoing operations and development programs, as it continues to navigate the complexities of the biopharmaceutical market.
About KYNTRA BIO, INC.
FibroGen, Inc. is a biopharmaceutical company focused on developing therapies for anemia and cancer. Its key products include roxadustat, an oral treatment for anemia in chronic kidney disease and myelodysplastic syndromes, and FG-3246, an antibody-drug conjugate targeting cancer. The company collaborates globally, with a core business model centered on drug development, licensing, and strategic partnerships in markets like China, Europe, and Japan.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov